AstraZeneca Launches Two Nutrition Websites

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 6
Volume 10
Issue 6

WILMINGTON, Del-AstraZeneca Pharmaceuticals has announced the launch of two new websites designed to make nutritional product information and nutritional news more readily available to US health care professionals.

WILMINGTON, Del—AstraZeneca Pharmaceuticals has announced the launch of two new websites designed to make nutritional product information and nutritional news more readily available to US health care professionals.

For the total parenteral nutrition professional, www.TPNpro.com contains articles, news feeds from Reuters News Service, links, tables and a calculator, daily facts from RealAge, and access to continuing education credits.

For information on AstraZeneca’s M.V.I.-12 (multivitamins for infusion) and M.V.I. Pediatric (multivitamins for infusion), including ordering information and patient brochures, professionals can visit www.MVI-us.com. 

Articles in this issue
ACS and NCCN Issue Cancer Pain Management Guidelines for Patients
Xeloda Approved for Metastatic Colorectal Cancer
Walking Improves Fatigue, Sleep in Breast Cancer Patients
Bezwoda 1985 Breast Cancer Transplant Study Fraudulent
Severity of Hot Flashes Worse in Breast Cancer Survivors
Tamoxifen Prevents BRCA2, But Not BRCA1, Breast Cancer
High TIMP-1 Levels May Promote Prostate Cancer Growth
Barriers to Colorectal Cancer Screening Among Minorities
Epoetin Reduces Need for Red Blood Cell Transfusions
French Researchers Discover How HIV Makes First Contact
‘Virtual Supercomputer’ Program for Cancer Drug Discovery
Agent Orange Linked to AML in Offspring
Turkish Towns Provide Genetic Link to Malignant Mesothelioma
President Allows Implementation of Patient Privacy Rule
Gleevec Is Approved for Chronic Myelogenous Leukemia
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients

13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients

Amanda Reynolds;Jonathan Klein;Joshua Feinberg;Bayle Smith-Salzberg;Pasang Sherpa;Vijaya Natarajan;Fleure Gallant;Ashley Anderson;Mukuhi Ng’ang’a
July 4th 2025
Article
Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

Experts discussed diagnosing and treating epithelioid sarcoma, emphasizing the importance of clinical history and the role of multiple multidisciplinary clinicians in care.

Diagnosing and Treating Patients With Epithelioid Sarcoma

ONCOLOGY Staff
July 4th 2025
Article

Experts discussed diagnosing and treating epithelioid sarcoma, emphasizing the importance of clinical history and the role of multiple multidisciplinary clinicians in care.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Busulfan/melphalan elicited higher PFS among patients with ISS2 or ISS3 disease, and melphalan-200 improved PFS in ISS1 disease.

Busulfan-Enhanced VRD Regimen Improves Efficacy in NDMM

Roman Fabbricatore
July 3rd 2025
Article

Busulfan/melphalan elicited higher PFS among patients with ISS2 or ISS3 disease, and melphalan-200 improved PFS in ISS1 disease.

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.

Bemarituzumab Regimen Improves Survival in FGFR2b+ Gastric/GEJ Cancer

Russ Conroy
July 3rd 2025
Article

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.